129 related articles for article (PubMed ID: 11535542)
1. Evaluation of epithelial cell proliferation rate in normal-appearing colonic mucosa as a high-risk marker for colorectal cancer.
Akedo I; Ishikawa H; Ioka T; Kaji I; Narahara H; Ishiguro S; Suzuki T; Otani T
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):925-30. PubMed ID: 11535542
[TBL] [Abstract][Full Text] [Related]
2. Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial.
Sandler RS; Baron JA; Tosteson TD; Mandel JS; Haile RW
Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):653-6. PubMed ID: 10919733
[TBL] [Abstract][Full Text] [Related]
3. Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67.
Hanna-Morris A; Badvie S; Cohen P; McCullough T; Andreyev HJ; Allen-Mersh TG
J Clin Pathol; 2009 Apr; 62(4):325-30. PubMed ID: 18474544
[TBL] [Abstract][Full Text] [Related]
4. Colorectal epithelial cell proliferative kinetics and risk factors for colon cancer in sporadic adenoma patients.
Bostick RM; Fosdick L; Grandits GA; Lillemoe TJ; Wood JR; Grambsch P; Louis TA; Potter JD
Cancer Epidemiol Biomarkers Prev; 1997 Dec; 6(12):1011-9. PubMed ID: 9419396
[TBL] [Abstract][Full Text] [Related]
5. Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel.
Scalmati A; Roncucci L; Ghidini G; Biasco G; Ponz de Leon M
Cancer Res; 1990 Dec; 50(24):7937-41. PubMed ID: 2253235
[TBL] [Abstract][Full Text] [Related]
6. Expansion of the epithelial cell proliferative compartment and frequency of adenomatous polyps in the colon correlate with the strength of family history of colorectal cancer.
Gerdes H; Gillin JS; Zimbalist E; Urmacher C; Lipkin M; Winawer SJ
Cancer Res; 1993 Jan; 53(2):279-82. PubMed ID: 8417821
[TBL] [Abstract][Full Text] [Related]
7. Levels of colorectal ornithine decarboxylase activity in patients with colon cancer, a family history of nonpolyposis hereditary colorectal cancer, and adenomas.
Love RR; Surawicz TS; Morrissey JF; Verma AK
Cancer Epidemiol Biomarkers Prev; 1992; 1(3):195-8. PubMed ID: 1306105
[TBL] [Abstract][Full Text] [Related]
8. Methodological problems in the use of rectal cell proliferation as a biomarker of colorectal cancer risk.
Biasco G; Paganelli GM; Santucci R; Brandi G; Barbara L
J Cell Biochem Suppl; 1994; 19():55-60. PubMed ID: 7823606
[TBL] [Abstract][Full Text] [Related]
9. Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical applications.
Berenzi A; Benetti A; Bertalot G; Rodolfi A; Portolani N; Giulini SM; Pulcini G; Vinco A; Tiberio G
Pathologica; 1992; 84(1090):155-63. PubMed ID: 1437304
[TBL] [Abstract][Full Text] [Related]
10. Colorectal mucosal expression of MSH2 as a potential biomarker of risk for colorectal neoplasms.
Sidelnikov E; Bostick RM; Flanders WD; Long Q; Seabrook ME
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2965-73. PubMed ID: 19861524
[TBL] [Abstract][Full Text] [Related]
11. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Krishnan K; Ruffin MT; Normolle D; Shureiqi I; Burney K; Bailey J; Peters-Golden M; Rock CL; Boland CR; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):447-53. PubMed ID: 11352853
[TBL] [Abstract][Full Text] [Related]
12. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
13. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
Rodins K; Cheale M; Coleman N; Fox SB
Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometry and in vitro tritiated thymidine labeling in normal rectal mucosa of patients at high risk of colorectal cancer.
Paganelli GM; Lalli E; Facchini A; Biasco G; Santucci R; Brandi G; Barbara L
Am J Gastroenterol; 1994 Feb; 89(2):220-4. PubMed ID: 8304307
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic effects of deoxycholic acid and butyrate on epithelial cell proliferation in the proximal and distal human colon.
Bartram HP; Englert S; Scheppach W; Dusel G; Richter F; Richter A; Kasper H
Z Gastroenterol; 1994 Jul; 32(7):389-92. PubMed ID: 7975774
[TBL] [Abstract][Full Text] [Related]
16. Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients.
Rulyak SJ; Lieberman DA; Wagner EH; Mandelson MT
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):470-6; quiz 407. PubMed ID: 17270502
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the MGMT and p16 genes in sporadic colorectal carcinoma and corresponding normal colonic mucosa.
Krakowczyk L; Strzelczyk JK; Adamek B; Zalewska-Ziob M; Arendt J; Półtorak S; Maciejewski B; Wiczkowski A
Med Sci Monit; 2008 Oct; 14(10):BR219-25. PubMed ID: 18830187
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
[TBL] [Abstract][Full Text] [Related]
20. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
